Skip to main content

Interventional Cardiology

Left Atrial Appendage Closure

Leading LAAC therapy with WATCHMAN FLX™ Left Atrial Closure Device

WATCHMAN FLX™ Left Atrial Appendage Closure Device

Built on the most studied and implanted LAAC device in the world, WATCHMAN FLX is a generation ahead for safety and simplicity and expands the treatable patient population.

An enlarged image of the WATCHMAN FLX device from the front view.

The WATCHMAN FLX LAAC Device performs with advanced procedural safety and simplicity in the widest range of patient anatomies, making it the most implanted FDA approved LAAC device.

The most studied LAAC device in the world

Advancing the standard of care with proven, safe, and trusted patient outcomes.

20 yrs

Of innovation and experience


LAAC programs established


Patients treated

Safety. Simplicity. Seal.

PINNACLE FLX, the WATCHMAN FLX US IDE Trial, demonstrated a 0.5% major adverse event rate, 100% effective LAA closure at 12 months, and a low 1.7% annualized ischemic stroke or systemic embolism rate at 24 months. 4, 5


Ischemic Stroke (2 of 400)4


All-cause death4


Pericardial effusions requiring open cardiac surgery4


Device embolization4


Major Adverse Event Rate 6*


Rate of effective LAA closure at 12 months**


Procedural success (395/400)6


Shorter procedure time than Legacy WATCHMAN 6,7

*Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention

**LAA closure at 12 months is defined as any peri-device flow with jet size ≤5mm per core laboratory-assessed TEE


Meta Analysis

The largest comparison of peri-procedural success and short-term outcomes of WATCHMAN FLX vs. Amplatzer™ Amulet™ reveals superior procedural safety, higher procedural success, and better LAA closure with WATCHMAN FLX.


The SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date 

Over one in three people with AFib feel trapped between the fear of having a stroke and fear of the risks associated with blood thinners. In fact, more than 4 in 5 people with AFib taking a blood thinner (83%) say they would be willing to try a different treatment to help reduce their risk of stroke.1

An illustration of a man between two large boulders that represent blood thinner side effects and having a stoke respectively.

WATCHMAN FLX LAAC device effectively reduces the risk of stroke—without the risk of bleeding that can come with the long-term use of blood thinners.2

This makes LAAC therapy an important option for people with a history or risk of serious bleeding on blood thinners.

Direct-to-patient LAAC program resources  

Support patients along their entire journey.

The direct-to-patient campaigns are uniquely designed to find, activate, and nurture potential candidates for the procedure. This innovative, multi-channel campaign delivers its message through TV advertisements and digital marketing programs encouraging patients to complete an online questionnaire to see if the procedure may be right for them. Since 2019, the campaign has reached more than 90% of AFib patients in the U.S.


TV, social media, and digital marketing delivers compelling message.


Online survey assesses eligibility and prompts internal conversation with physician.


Dedicated patient support and education programs build confidence.

100,000+ qualified patients have completed the eligibility survey on

WATCHMAN Calibration Program (WCP)

With the WATCHMAN Calibration Program, you have a trusted partner to help enhance the patient experience and leverage our expertise to help increase patient volumes and eliminate barriers to productivity.  

The WATCHMAN Calibration Program focuses on these key objectives:

  • Discovery: Interviews with key program stakeholders to understand the current day-to-day process
  • Strategic Planning: We create an Action Plan with recommended solutions based on real-time feedback and data.
  • Application: You decide which solutions to prioritize within your program and we provide ongoing support to help you succeed.
A medical professional showing data on a tablet to a paitent.

Improve referral management

  • Analyze and grow referrals using data-driven insights
  • Drive therapy awareness through education and activation
  • Identify and manage patients using technology opportunities

Increase program efficiency

  • Coordinate care between the hospital and clinic
  • Improve operations in the cardiovascular service line and the cath lab
  • Discuss and refine hospital marketing processes

WATCHMAN Reimbursement

National coverage for a broad range of patients including:

  • Weighted average increase for LAAC (DRG 273-274) in 2023 is 6.9% or an additional $1540
  • Broad commercial payer coverage with national payers covering over 99% of commercially covered lives
  • WATCHMAN CMS reimbursement has increased 89% over the last 8 years
  • Since 2015, CMS reimbursement has increased $11,003 nationally

WATCHMAN health economics and market access support

A dedicated team of WATCHMAN-focused health economics professionals help you understand the economics of your LAAC program at various levels through:

Program economic overview
Using publicly available data, our team identifies current year reimbursement, historic cost detail, including LOS, and DRG mix while comparing hospital specific benchmarks to national, state, and core-base statistical areas (CBSA)

Program economic deep-dive
Using customer-specific ICD-10-CM/PCS data, our team analyzes coding, charges, and direct costs of the LAAC program to identify opportunities to improve revenue cycle management, calculate contribution margin, and compare hospital specific performance year over year by fiscal or calendar year.  

WATCHMAN FLX LAAC Device Reimbursement Guide

Resources and tools:  WATCHMAN download center

  • Coding and claims for WATCHMAN procedures
  • National coverage determination
  • Resources supporting prior authorization, appeals, and beyond

Contact Us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.


1. The Harris Poll online survey. Boston Scientific. SH-574213-AA Accessed March 28, 2019
2. PINNACLE FLX: Final Report of 24-Month Results, Late Breaking Presentation at TVT 2021 by Dr. Saibal Kar
3. BSC Data on file
4. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021
5. PINNACLE FLX: Final Report of 24-Month Results, Late Breaking Presentation at TVT 2021 by Dr. Saibal Kar.
6. Kar, PINNACLE FLX; 12 Month Outcomes, CIRCULATION, 2021
7. Reddy VY, et al. JACC 2017; 70(24): 2964-2975